Kodiak Sciences Inc
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $96.80
- 52-Week Range
- $19.04 – $112.79
- Market Cap
- $6.40B
- P/E (TTM)
- —
- EPS (TTM)
- -4.08
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 499.03
- PEG Ratio
- —
- Return on Equity
- -1360.91%
- Return on Assets
- -74.56%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 1.70
- Debt/Equity
- 3.70
- Total Debt
- $46.56M
- Free Cash Flow
- $-70.67M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $6.34B
Market Snapshot
About
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic retinal diseases. The company's proprietary platform focuses on developing longer-lasting treatments for conditions like wet age-related macular degeneration and diabetic retinopathy. Kodiak's lead product candidate is designed to reduce treatment burden through extended dosing intervals.